

type of report	Current report
number	5/2012
company	PHARMENA

Obtaining a patent in Europe

With reference to report no. 39/2011 of 9th September 2011 (Information on intent to grant patent in Europe), the Management Board of PHARMENA S.A. declares that on 10th February 2012, CORTRIA CORPORATION, a subsidiary company of PHARMENA S.A. received notification that it was granted a patent no. EP 1919466 by European Patent Office.

The patent will provide protection for the use of 1-methylnicotinamide (1-MNA) in combination with statins in the treatment of lipid profile disorders on leading European markets, including: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Holland, Hungary, Ireland, Island, Italy, Liechtenstein, Lithuania, Luxemburg, Monaco, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom.

This patent is of great importance to the process of commercialisation of the 1-MNA project, due to the fact that European market constitutes ca. 33% of the world market value of dyslipidemia, which is estimated at 40 billion USD. Dyslipidemia is a disease characterized by lipid profile disorders. Statins are medications that lower the levels of lipoproteins, in particular total cholesterol, LDL lipoproteins, VLDL lipoproteins. Potentially, 1-MNA in combination with statins may provide complete treatment, through correction of all lipid profile parameters.

The information is made public due to the fact that it may influence the asset valuation of PHARMENA S.A. in the form of patent application described in the report, which CORTRIA CORPORATION (a subsidiary company of PHARMENA S.A.) possesses rights to, as well as because of participation in potential revenue resulting from commercialisation of the aforementioned patent application.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board